Clinical aspects and biological bases of drug-resistant epilepsies
- PMID: 10210025
- DOI: 10.1016/s0920-1211(98)00106-5
Clinical aspects and biological bases of drug-resistant epilepsies
Abstract
The definition of drug-resistant epilepsy (DRE) is elusive and still controversial owing to some unresolved questions such as: how many drugs should be tried before a patient is considered intractable; to which extent side-effects may be acceptable; how many years are necessary before establishing drug resistance. In some cases, the view of epilepsy as a progressive disorder constitutes another important issue. Despite the use of new antiepileptic drugs (AEDs), intractable epilepsy represents about 20-30% of all cases, probably due to the multiple pathogenetic mechanisms underlying refractoriness. Several risk factors for pharmacoresistance are well known, even if the list of clinical features and biological factors currently accepted to be associated with difficult-to-treat epilepsy is presumably incomplete and, perhaps, disputable. For some of these factors, the biological basis may be common, mainly represented by mesial temporal sclerosis or by the presence of focal lesions. In other cases, microdysgenesis or dysplastic cortex, with abnormalities in the morphology and distribution of local-circuit (inhibitory) neurons, may be responsible for the severity of seizures. The possible influence of genes in conditioning inadequate intraparenchimal drug concentration, and the role of some cytokines determining an increase in intracellular calcium levels or an excessive growth of distrophic neurites, constitute other possible mechanisms of resistance. Several hypotheses on the mechanisms involved in the generation of DRE have been indicated: (a) ontogenic abnormalities in brain maturation; (b) epilepsy-induced alterations in network, neuronal, and glial properties in seizure-prone regions such as the hippocampus; (c) kindling phenomenon; (d) reorganization of cortical tissue in response to seizure-induced disturbances in oxygen supply. Such hypotheses need to be confirmed with suitable experimental models of intractable epilepsy that are specifically dedicated, which have until now been lacking.
Similar articles
-
Strategies for the development of drugs for pharmacoresistant epilepsies.Epilepsia. 1994;35 Suppl 5:S10-21. doi: 10.1111/j.1528-1157.1994.tb05959.x. Epilepsia. 1994. PMID: 7518767 Review.
-
Focal epilepsies in adult patients attending two epilepsy centers: classification of drug-resistance, assessment of risk factors, and usefulness of "new" antiepileptic drugs.Epilepsia. 2012 Apr;53(4):733-40. doi: 10.1111/j.1528-1167.2012.03416.x. Epub 2012 Feb 23. Epilepsia. 2012. PMID: 22360822
-
The intrinsic severity hypothesis of pharmacoresistance to antiepileptic drugs.Epilepsia. 2013 May;54 Suppl 2:33-40. doi: 10.1111/epi.12182. Epilepsia. 2013. PMID: 23646969 Review.
-
ABC transporters during epilepsy and mechanisms underlying multidrug resistance in refractory epilepsy.Epilepsia. 2007;48 Suppl 5:140-9. doi: 10.1111/j.1528-1167.2007.01302.x. Epilepsia. 2007. PMID: 17910594 Review.
-
Knockout of P-glycoprotein does not alter antiepileptic drug efficacy in the intrahippocampal kainate model of mesial temporal lobe epilepsy in mice.Neuropharmacology. 2016 Oct;109:183-195. doi: 10.1016/j.neuropharm.2016.06.007. Epub 2016 Jun 7. Neuropharmacology. 2016. PMID: 27288003
Cited by
-
Involvement of p38 MAPK in the Drug Resistance of Refractory Epilepsy Through the Regulation Multidrug Resistance-Associated Protein 1.Neurochem Res. 2015 Jul;40(7):1546-53. doi: 10.1007/s11064-015-1617-y. Epub 2015 Jun 20. Neurochem Res. 2015. PMID: 26092535 Free PMC article.
-
Deep Brain Stimulation Increases Seizure Threshold by Altering REM Sleep and Delta Powers During NREM Sleep.Front Neurol. 2020 Aug 12;11:752. doi: 10.3389/fneur.2020.00752. eCollection 2020. Front Neurol. 2020. PMID: 32903424 Free PMC article.
-
Chronic homocysteine exposure causes changes in the intrinsic electrophysiological properties of cultured hippocampal neurons.Exp Brain Res. 2013 Apr;225(4):527-34. doi: 10.1007/s00221-012-3392-1. Epub 2013 Jan 10. Exp Brain Res. 2013. PMID: 23307157
-
Anticonvulsant and related neuropharmacological effects of the whole plant extract of Synedrella nodiflora (L.) Gaertn (Asteraceae).J Pharm Bioallied Sci. 2012 Apr;4(2):140-8. doi: 10.4103/0975-7406.94816. J Pharm Bioallied Sci. 2012. PMID: 22557925 Free PMC article.
-
Anticonvulsant enaminones depress excitatory synaptic transmission in the rat brain by enhancing extracellular GABA levels.Br J Pharmacol. 2005 Aug;145(7):945-53. doi: 10.1038/sj.bjp.0706250. Br J Pharmacol. 2005. PMID: 15912138 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical